The EU-funded project AIDPATH, a collaboration between twelve partners from seven countries, is aiming to increase patient’s access to CAR-T cell therapy, a promising treatment for blood cancers such as leukemia and lymphoma. After developing a platform for automated CAR-T production, the first manufacturing part of the platform has been moved to its final location at the University Hospital Würzburg, where first tests have been already conducted. This unique platform will now undergo further rigorous testing to ensure that it meets the highest standards of precision, safety, and efficiency by utilizing AI technology to manufacture genetically engineered immune cells.